Stock Earnings

Question 1

Quels sont les états financiers clés de Ultragenyx Pharmaceutical Inc ?

Accepted Answer

Selon le dernier état financier (Form-10K), Ultragenyx Pharmaceutical Inc a un total d'actifs de $1,503, un bénéfice net loss de $-569

Question 2

Quels sont les ratios financiers clés pour RARE ?

Accepted Answer

Le ratio de liquidité de Ultragenyx Pharmaceutical Inc est 1.2, la marge nette est -101.6, les ventes par action sont de $6.18.

Question 3

Comment les revenus de Ultragenyx Pharmaceutical Inc sont-ils répartis par segment ou géographie ?

Accepted Answer

Ultragenyx Pharmaceutical Inc largest revenue segment is Mepsevii, at a revenue of 30,350,000 in the most earnings release.For geography, North America is the primary market for Ultragenyx Pharmaceutical Inc, at a revenue of 340,463,000.

Question 4

Ultragenyx Pharmaceutical Inc est-elle rentable ?

Accepted Answer

no, selon les derniers états financiers, Ultragenyx Pharmaceutical Inc a un bénéfice net loss de $-569

Question 5

Ultragenyx Pharmaceutical Inc a-t-elle des passifs ?

Accepted Answer

yes, Ultragenyx Pharmaceutical Inc a un passif de 1,248

Question 6

Combien d'actions en circulation Ultragenyx Pharmaceutical Inc a-t-elle ?

Accepted Answer

Ultragenyx Pharmaceutical Inc a un total d'actions en circulation de 92.48

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	610	560	434	363	351	271
Revenue Growth (YoY)	27%	28.99%	20%	3%	30%	163%
Cost of Revenue	89	76	45	28	16	6
Gross Profit	520	483	389	335	335	264
Selling, General & Admin	337	321	309	278	220	182
Research & Development	688	692	644	702	496	411
Operating Expenses	1,025	1,019	958	983	717	595
Other Non Operating Income (Expenses)	-13	-3	0	-44	-31	-32
Pretax Income	-530	-567	-608	-701	-453	-185
Income Tax Expense	2	1	-1	5	1	1
Net Income	-532	-569	-606	-707	-454	-186
Net Income Growth	-9%	-6%	-14%	56%	144%	-54%
Shares Outstanding (Diluted)	98.46	90.53	73.54	69.9	67.8	60.8
Shares Change (YoY)	14%	23%	5%	3%	12%	7%
EPS (Diluted)	-5.41	-6.28	-8.24	-10.12	-6.7	-3.07
EPS Growth	-20%	-24%	-18%	51%	118%	-56.99%
Free Cash Flow	-442	-434	-521	-526	-411	-176
Free Cash Flow Per Share	-4.48	-4.79	-7.08	-7.52	-6.06	-2.89
Gross Margin	85.24%	86.25%	89.63%	92.28%	95.44%	97.41%
Operating Margin	-82.78%	-95.53%	-131.1%	-178.51%	-108.54%	-121.77%
Profit Margin	-87.21%	-101.6%	-139.63%	-194.76%	-129.34%	-68.63%
Free Cash Flow Margin	-72.45%	-77.5%	-120.04%	-144.9%	-117.09%	-64.94%
EBITDA	-470	-500	-543	-630	-368	-318
EBITDA Margin	-77.04%	-89.28%	-125.11%	-173.55%	-104.84%	-117.34%
D&A For EBITDA	35	35	26	18	13	12
EBIT	-505	-535	-569	-648	-381	-330
EBIT Margin	-82.78%	-95.53%	-131.1%	-178.51%	-108.54%	-121.77%
Effective Tax Rate	-0.37%	-0.17%	0.16%	-0.71%	-0.22%	-0.54%

Ultragenyx Pharmaceutical Inc (RARE) Price

RARE Stock Price Chart

RARE Income

Follow-Up Questions